Search

Author/Creator DeAngelo, D. J.

1. P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY. (23rd June 2022)

Authors:
Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
903
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE. (23rd June 2022)

Authors:
Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
904
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY. (23rd June 2022)

Authors:
Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
905
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES. (23rd June 2022)

Authors:
George, T.; Karner, K. H.; Moser, K. A.; Rets, A.; Reiter, A.; Radia, D. H.; Deininger, M.; Lin, H.-M.; Dimitrijević, S.; DeAngelo, D. J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
917
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P1049: A PHASE 2 STUDY OF BEZUCLASTINIB (CGT9486), A NOVEL, HIGHLY SELECTIVE, POTENT KIT D816V INHIBITOR, IN ADULTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (APEX): METHODS, BASELINE DATA, AND EARLY INSIGHTS. (23rd June 2022)

Authors:
DeAngelo, D. J.; Pullarkat, V.; Piris-Villaespesa, M.; George, T. I.; Patel, J. L.; Ustun, C.; Bose, P.; Heaney, M. L.; Pilla, A.; Massaro, M.; Exter, B.; Jolin, H. A.; Mikhak, Z.; Tashi, T.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
939
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3. (23rd June 2022)

Authors:
Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; O'Dwyer, K. M.; Arellano, M. L.; Lin, Y.; Baer, M. R.; Schiller, G. J.; Subklewe, M.; Abedi, M.; Minnema, M. C.; Wierda, W. G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
256
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML. (23rd June 2022)

Authors:
Daver, N. G.; Montesinos, P.; Aribi, A.; Martinelli, G.; Altman, J.; Roboz, G.; Wang, E. S.; Burke, P. W.; Jeyakumar, D.; Walter, R. B.; DeAngelo, D. J.; Erba, H. P.; Advani, A.; Gastaud, L.; Thomas, X.; Todisco, E.; Pemmaraju, N.; Mendez, L.; de la Fuente, A.; Gaidano, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
454
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS. (23rd June 2022)

Authors:
Apperley, J.; Kantarjian, H.; Deininger, M.; Abruzzese, E.; Cortes, J.; Chuah, C.; DeAngelo, D. J.; DiPersio, J.; Hochhaus, A.; Lipton, J.; Nicolini, F.; Pinilla-Ibarz, J.; Rea, D.; Rosti, G.; Rousselot, P.; Mauro, M.; Shah, N.; Talpaz, M.; Vorog, A.; Ren, X.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
602
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN. (23rd June 2022)

Authors:
Pemmaraju, N.; Martinelli, G.; Todisco, E.; Tarella, C.; Montesinos, P.; Lane, A. A.; Erba, H. P.; Sweet, K. L.; Walter, R. B.; Deconinck, E.; Wang, E. S.; Aribi, A.; Ulrikson, M. L.; Levy, M. Y.; Lebon, D.; Marconi, G.; DeAngelo, D. J.; Rizzieri, D.; Konopleva, M.; Sloss, C. M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1708
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY. (23rd June 2022)

Authors:
Daver, N. G.; Wei, A. H.; Stein, E. M.; DeAngelo, D. J.; Pathak, D.; Xu, Y.; Grzesiak, S.; Venditti, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1729
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search